Document is current
Any future updates will be listed below
-
Authors
Tvingsholm, Siri Amanda
Frej, Marcus Svensson
Rafa, Vibeke Mindahl
Hansen, Ulla Kring
Ormhøj, Maria
Tyron, Alexander
Jensen, Agnete W P https://orcid.org/0000-0001-8868-7481
Kadivar, Mohammad https://orcid.org/0000-0003-1499-191X
Bentzen, Amalie Kai
Munk, Kamilla K
Aasbjerg, Gitte N
Ternander, Jeppe S H
Heeke, Christina
Tamhane, Tripti
Schmess, Christian https://orcid.org/0000-0003-4883-2642
Funt, Samuel A.
Kjeldsen, Julie Westerlin
Kverneland, Anders Handrup https://orcid.org/0000-0002-9883-936X
Met, Özcan
Draghi, Arianna https://orcid.org/0000-0002-5894-6750
Jakobsen, Søren Nyboe
Donia, Marco https://orcid.org/0000-0003-4966-9752
Marie Svane, Inge
Hadrup, Sine Reker https://orcid.org/0000-0002-5937-4344
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02278887 at ClinicalTrials.govnct03047928 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
https://doi.org/10.1136/jitc-2020-000848
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
https://doi.org/10.1136/jitc-2023-008372
Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
https://doi.org/10.1136/bmjgast-2022-000989
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2024-010575
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
https://doi.org/10.1136/jitc-2023-006847
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
Documents that mention this clinical trial
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
https://doi.org/10.1136/jitc-2023-006847
Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4<sup>+</sup> and CD8<sup>+</sup> T cells for immunotherapy of cancer
https://doi.org/10.1136/jitc-2022-004709
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
https://doi.org/10.1136/jitc-2023-006755
-
Funding
Funding for this research was provided by:
Innovationsfonden (9122-00084)
The Danish Ministry of Research and Education, Empowering cancer immunotherapy in Denmark (N/A)
Danmarks Frie Forskningsfond (4004-00422B)
Lundbeckfonden (R190-2014-4178)
European Research Council (N/A)
- License Information
